Patents

News Patents

• Anergis obtains U.S. patent for AllerT

  Anergis has been granted patent protection for its AllerT birch pollen allergy treatment in the U.S. The patent No. 8,343,503 granted by the U.S. Patent Office broadly covers composition of matter and medical use of AllerT, the lead product of Anergis. AllerT is composed of a set of three contiguous more

• SYGNIS is granted the European and US patent for a very versatile and efficient drug screening platform

  SYGNIS Pharma AG has been granted the European and US patent for a new basic technology for the detection of protein-protein interactions, a screening platform for the development of novel drugs.  Protein-protein interactions falls within the scope of proteomics, a field that is growing in importanc more

• The United States, New Zealand & Mexico Issue Patent for New Allon Platform

  Allon Therapeutics Inc. announced that the United States, New Zealand and Mexican patent authorities have each issued composition of matter patents for a new family of peptides that the Company believes has the potential to be developed to treat neurological and neurodegenerative diseases. This new more

White papers Patents

• Outsourcing R&D Innovation takes on New Meaning
  

  Innovative drugs are the lifeblood of pharmaceutical companies, but the cost of developing them is rising to unsustainable levels. Pharma executives are already saying that as the economy falters, they foresee bleak prospects and mergers unless their companies get more innovative drugs into their pipelines. The clock is ticking on the race to increase productivity, as key patents worth a projected $30 billion in revenue will expire between 2010 and 2013, opening the floodgates to competition from generics, according to Barbara Ryan, an analyst at Deutsche Bank. This imperative is propelling increased outsourcing of R&D operations as companies trim overcapacity. more

• DKSH Performance Materials: Introduction of new program to source products
  

  Even under pressure to reduce costs, effective cooperation and hard work will always find a way to fulfill expectations. Most global players in the pharmaceutical industry are facing dramatic changes: blockbuster products launched in the 1990s will lose their patents over the next few years and face competition which will threaten their steady earnings more

• Outsourcing in Pharmaceutical Industry

  Pharmaceutical industry is constantly undergoing a change. In the past pharmaceuticals had a different strategy, companies use to build all the products internally and confine access to information or resources to third parties. The past situation is changing; in-house resources are getting exhausted with a very thin product pipeline and in addition many drugs are going off patent by 2008 hampering company sales and competitiveness. It takes $800 million and 20 years for... more

Publications Patents

• [News of the Week] Around the World

  In science news around the world, the U.S. Supreme Court backed the agribusiness firm Monsanto on its soybean patents; the Institut Pasteur has denied accusations by a government watchdog that it misleads research donors; and a director at Charité University Hospital is preparing to examine how Cold more

• Seven days: 10–16 May 2013

  Seven days: 10–16 May 2013 Nature 497, 7449 (2013). http://www.nature.com/doifinder/10.1038/497292a The week in science: Endangered ecosystems listed, GM patents protected, and wild poliovirus detected in Somalia. more

• [News & Analysis] Intellectual Property: In a Flurry of Metaphors, Justices Debate a Limit on Gene Patents

  The U.S. Supreme Court is trying to determine whether patents on the cancer-linked genes BRCA1and BRCA2 are legitimate. more

Market studies Patents

• Tanzania Pharmaceuticals and Healthcare Report Q3 2012

  BMI View: It is vital the Tanzanian government assesses its medicine procurement systems. The expiry of medicines does not bode well for the state and its high reliance on donor funding for the healthcare sector, particularly as reports have highlighted the poor availability of essential medicines i more

• India Pharmaceuticals and Healthcare Report Q3 2012

  BMI View: India's pharmaceutical regulator should drop its requirement for local clinical trials in order for a new medicine to receive approval. The country does not have the necessary number of trained professionals to effectively monitor the costly and timely process. Patients would benefit from more

• Global Biosimilars Market Report: 2012 Edition

  The biosimilar market is presently a small segment of the pharmaceutical industry. However, in the years to come, the market for biosimilars has huge growth opportunity despite of the high entry barriers. The governments in the developed countries are desperately trying to control their national hea more

Websites Patents